Sign In
Buy FMS
$25.66
-0.0400 (-0.156%)
At Close: Jul 31, 2026
Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy?
10:55am, Wednesday, 06'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO
08:33pm, Tuesday, 05'th Nov 2024
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings.
Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript
02:34pm, Tuesday, 05'th Nov 2024
Fresenius Medical Care AG (NYSE:FMS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer an
Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024
07:00am, Tuesday, 05'th Nov 2024
Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional E
Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock?
10:46am, Tuesday, 22'nd Oct 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wi
Here's Why Fresenius (FMS) is a Strong Value Stock
10:45am, Tuesday, 08'th Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Fresenius Medical Care: Let's Look At The Upside
04:04pm, Friday, 04'th Oct 2024
Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth
Here's Why Fresenius (FMS) is a Strong Momentum Stock
10:50am, Friday, 04'th Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives
08:11am, Thursday, 03'rd Oct 2024
Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
10:16am, Friday, 27'th Sep 2024
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
10:41am, Friday, 20'th Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
10:56am, Wednesday, 18'th Sep 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
01:50pm, Monday, 09'th Sep 2024
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adop
